Devices & Specs


G-Tube Rapid Reinsertion Tray


The global enteral feeding devices market was valued at US 2.41 billion in 2018 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.89% during the forecast period of 2019-2025.

Unmet medical needs in emerging markets such as Brazil, India, and China, as well as the Middle East and Africa and the introduction of new products enabled with technological advancements are expected to serve this market as future growth opportunities.

The G-tube Rapid Reinsertion Tray allows for rapid reinsertion at the bedside thereby reducing the time the tube is removed from the stoma tract eliminating the possibility of collapse of the tissue walls and the stoma tract. It also reduces the costs associated with reinserting the tube due to accidental extrusion, a leaking tube, blocked tube, peri-stomal infection, tubal fungal colonization as well as routine exchange after extended use. The rapid reinsertion also eliminates the need for hospital admission, endoscopic or surgical extended use. The rapid reinsertion also eliminates the need for hospital admission, endoscopic or surgical intervention, anesthesia and subsequent post-op care as well as the likelihood of readmission to a healthcare facility after discharge. The more rapidly the G-tube is reinserted the less likely the patient will miss nutritional intervention which decreases the risk of sepsis and intra-abdominal abscesses, as well as pneumonia and weight loss, pressure ulcers and urinary tract infections.

The G-tube Rapid Reinsertion Tray not only contributes to the general health and well-being of the patient by allowing continuous nutrition and decreasing the likelihood of infections, but also reduces soaring medical care costs in both the United States and worldwide. The G-tube Rapid Reinsertion Tray has parent coverage in the US, the European Union, India and Japan. The population of these countries includes approximately 3.1 billion people, over 60,000 hospitals, numerous nursing homes, urgent care centers, home health care services, as well as United States VA hospitals and clinics at home and abroad.

G-tube Rapid Reinsertion Tray Benefits 

BETTER CARE
Allows for rapid reinsertion at the bedside thereby reducing the time the tube is removed from the stoma tract eliminating the possibility of collapse of the tissue walls and the stoma tract.

REDUCED COSTS
Reduces the costs associated with reinserting the tube due to accidental extrusion, a leaking tube, blocked tube, peri-stomal infection, tubal fungal colonization as well as routine exchange after extended use.

REDUCED COMPLICATIONS
Reduces delays in nutritional intervention which decreases the risk of sepsis and intra-abdominal abscesses, as well as pneumonia and weight loss, pressure ulcers and urinary tract infections.

Nasal Epistaxis Clamp


In the United States alone every year over fifty million adults and children will suffer from a nosebleed. The causes are many, including minor trauma, elevated blood pressure, dry nasal mucous membrane, excessive amounts of prescribed blood thinners, as well as nose picking and repeated rubbing. The great majority of patients go to their local Emergency Department or urgent care center seeking help to control the bleeding, often by ambulance, thereby drastically increasing the overall cost of medical care in the United States.

Clinical research has determined that 95% of nosebleeds occur in the anterior portion of the nose and can be safely controlled at home with proper compression of the nostrils for five to ten minutes.

The rapid control device described here is the first new design of an external compression device to control nosebleeds in over two decades. It was ergonomically designed based on nasal anatomy for maximal coverage of the intranasal bleeding site. It has no-slip technology due to a new age design of over two hundred 2mm circular raised bubbles on the interior surface of the device. These bubbles not only prevent slippage, but also increase the compression surface area by 60% over a flat surface compression device, creating 4.69 square inches of surface area.

At the same time the limbs of the device were designed to generate three to five pounds per square inch of external compression force to the nostrils to control active bleeding, compared to the currently marketed device that creates less than one half pound per square inch of compression force with a surface area of less than half a square inch. The overall differences in both design and clinical effectiveness are dramatic.

The device is easy to apply by pulling the limbs apart, then applying them to the entire nostril surface.

It is composed of a plastic based material, and designed for single person usage while being washable and reusable by that individual. It is presently patent pending, manufactured and packaged with easy to read instructions.